WO2017100305A8 - Composition of antibody construct-agonist conjugates and methods of use thereof - Google Patents

Composition of antibody construct-agonist conjugates and methods of use thereof Download PDF

Info

Publication number
WO2017100305A8
WO2017100305A8 PCT/US2016/065353 US2016065353W WO2017100305A8 WO 2017100305 A8 WO2017100305 A8 WO 2017100305A8 US 2016065353 W US2016065353 W US 2016065353W WO 2017100305 A8 WO2017100305 A8 WO 2017100305A8
Authority
WO
WIPO (PCT)
Prior art keywords
antibody construct
methods
composition
agonist conjugates
disclosed
Prior art date
Application number
PCT/US2016/065353
Other languages
French (fr)
Other versions
WO2017100305A2 (en
WO2017100305A3 (en
Inventor
Peter Armstrong Thompson
Badreddin EDRIS
Original Assignee
Opi Vi - Ip Holdco Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/173,075 external-priority patent/US20170158772A1/en
Application filed by Opi Vi - Ip Holdco Llc filed Critical Opi Vi - Ip Holdco Llc
Priority to CA3007311A priority Critical patent/CA3007311A1/en
Priority to DE212016000029.2U priority patent/DE212016000029U1/en
Priority to EP16873755.9A priority patent/EP3386536A4/en
Priority to US15/624,441 priority patent/US20170298139A1/en
Publication of WO2017100305A2 publication Critical patent/WO2017100305A2/en
Publication of WO2017100305A3 publication Critical patent/WO2017100305A3/en
Publication of WO2017100305A8 publication Critical patent/WO2017100305A8/en
Priority to US17/066,776 priority patent/US20210139604A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Various antibody construct compositions are disclosed. The compositions of antibody construct-immune stimulatory compound conjugates are also provided. Additionally provided are the methods of preparation and used of the antibody construct-immune stimulatory compound conjugates. This includes methods for treating disorders, such as cancer. A genus of STING agonist compounds and method of synthesis is also disclosed.
PCT/US2016/065353 2015-12-07 2016-12-07 Composition of antibody construct-agonist conjugates and methods of use thereof WO2017100305A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA3007311A CA3007311A1 (en) 2015-12-07 2016-12-07 Compositions of antibody construct-agonist conjugates and methods of use thereof
DE212016000029.2U DE212016000029U1 (en) 2015-12-07 2016-12-07 Compositions of antibody construct agonist conjugates
EP16873755.9A EP3386536A4 (en) 2015-12-07 2016-12-07 Composition of antibody construct-agonist conjugates and methods of use thereof
US15/624,441 US20170298139A1 (en) 2015-12-07 2017-06-15 Compositions of antibody construct-agonist conjugates and methods of use thereof
US17/066,776 US20210139604A1 (en) 2015-12-07 2020-10-09 Compositions of antibody construct-agonist conjugates and methods of use thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562264260P 2015-12-07 2015-12-07
US62/264,260 2015-12-07
US15/173,075 US20170158772A1 (en) 2015-12-07 2016-06-03 Compositions of antibody construct - agonist conjugates and methods of use thereof
US15/173,075 2016-06-03
US201662371141P 2016-08-04 2016-08-04
US62/371,141 2016-08-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/173,075 Continuation US20170158772A1 (en) 2015-12-07 2016-06-03 Compositions of antibody construct - agonist conjugates and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/624,441 Continuation US20170298139A1 (en) 2015-12-07 2017-06-15 Compositions of antibody construct-agonist conjugates and methods of use thereof

Publications (3)

Publication Number Publication Date
WO2017100305A2 WO2017100305A2 (en) 2017-06-15
WO2017100305A3 WO2017100305A3 (en) 2017-07-20
WO2017100305A8 true WO2017100305A8 (en) 2017-09-08

Family

ID=59013332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/065353 WO2017100305A2 (en) 2015-12-07 2016-12-07 Composition of antibody construct-agonist conjugates and methods of use thereof

Country Status (4)

Country Link
EP (1) EP3386536A4 (en)
CA (1) CA3007311A1 (en)
DE (1) DE212016000029U1 (en)
WO (1) WO2017100305A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016304899B2 (en) 2015-08-13 2018-11-08 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
KR20230149857A (en) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Antibody adjuvant conjugates
AR109788A1 (en) 2016-10-04 2019-01-23 Merck Sharp & Dohme BENZO COMPOUNDS [B] THIOPHEN AS STING AGONISTS
JOP20170192A1 (en) * 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co Cyclic dinucleotide
CA3049842A1 (en) * 2017-02-02 2018-08-09 Silverback Therapeutics, Inc. Construct-peptide compositions and methods of use thereof
AR113224A1 (en) * 2017-04-28 2020-02-19 Novartis Ag ANTIBODY CONJUGATES INCLUDING A STING AGONIST
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
EP3661498A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. BENZO[b]THIOPHENE STING AGONISTS FOR CANCER TREATMENT
US11312772B2 (en) 2017-08-04 2022-04-26 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
CN107365361B (en) * 2017-08-21 2020-05-19 中国药科大学 Repeat domain anchored proteins that bind to PD-L1 and uses thereof
US10953032B2 (en) * 2017-08-31 2021-03-23 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US10947263B2 (en) * 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. Compounds compositions, and methods for the treatment of disease
US11707531B2 (en) * 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
CN111566119A (en) 2017-11-10 2020-08-21 武田药品工业有限公司 STING modulator compounds and methods of making and using
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
TWI793294B (en) 2018-04-03 2023-02-21 美商默沙東有限責任公司 Sting agonist compounds
JP2021525706A (en) 2018-05-25 2021-09-27 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Tricyclic heterocyclic compound as a STING activator
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
JP7254818B2 (en) 2018-09-06 2023-04-10 第一三共株式会社 Novel cyclic dinucleotide derivatives and their antibody-drug conjugates
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
WO2020247973A1 (en) * 2019-06-03 2020-12-10 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
EP3980057A1 (en) 2019-06-04 2022-04-13 Institut Curie Methods of producing shiga toxin b-subunit (stxb) monomers and oligomers, and uses thereof
CN114786729B (en) 2019-07-19 2023-12-19 免疫传感器治疗股份有限公司 Antibody-STING agonist conjugates and their use in immunotherapy
JP2022543086A (en) 2019-08-02 2022-10-07 メルサナ セラピューティクス インコーポレイテッド Bis-[N-((5-carbamoyl)-1H-benzo[d]imidazol-2-yl)-pyrazole-5-carboxamide] derivatives as STING (interferon gene stimulator) agonists for the treatment of cancer and related Compound
US20220313835A1 (en) * 2019-09-03 2022-10-06 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
WO2021110987A1 (en) 2019-12-06 2021-06-10 Life & Soft Methods and apparatuses for diagnosing cancer from cell-free nucleic acids
CN111233850B (en) * 2020-01-21 2022-09-23 南开大学 Naphthol derivative containing benzothiazole amino and heteroaryl and preparation method and application thereof
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
EP4115909A1 (en) 2020-03-06 2023-01-11 Daiichi Sankyo Company, Limited Antibody-drug conjugate including novel cyclic dinucleotide derivative
EP4117790A1 (en) 2020-03-13 2023-01-18 Hephaistos-Pharma Detoxified lipopolysaccharides (lps), naturally non-toxic lps, and uses thereof
EP4149457A1 (en) 2020-05-15 2023-03-22 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with immune checkpoint inhibitors
JP2023532304A (en) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． Anti-ASGR1 antibody conjugates and uses thereof
EP3943505A1 (en) 2020-07-22 2022-01-26 Encefa Cd38-binding cd31 peptides and uses thereof
EP4209506A1 (en) 2020-09-02 2023-07-12 Daiichi Sankyo Company, Limited Novel endo-?-n-acetylglucosaminidase
US20220168330A1 (en) 2020-11-09 2022-06-02 Takeda Pharmaceutical Company Limited Antibody drug conjugates
US20240033366A1 (en) 2020-12-02 2024-02-01 Institut Curie FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF
KR20230152073A (en) 2021-02-26 2023-11-02 브레누스 파마 Non-autologous multi-stress cancer cells and their use for vaccination and treatment of cancer
CA3226976A1 (en) 2021-07-23 2023-01-26 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with cytokines
CA3231944A1 (en) 2021-09-16 2023-03-23 Carole GUILLONNEAU Anti-human cd45rc binding domains and uses thereof
WO2023109942A1 (en) * 2021-12-17 2023-06-22 Jacobio Pharmaceuticals Co., Ltd. Compound-linker constructs comprising novel compounds useful as sting agonists and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014842A1 (en) * 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
KR100477070B1 (en) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 Enhancing the efficacy of pharmaceuticals by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
SG11201406592QA (en) * 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
AU2015205753A1 (en) * 2014-01-10 2016-07-21 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating HER2 positive tumors

Also Published As

Publication number Publication date
WO2017100305A2 (en) 2017-06-15
DE212016000029U1 (en) 2017-07-30
EP3386536A2 (en) 2018-10-17
EP3386536A4 (en) 2019-07-31
WO2017100305A3 (en) 2017-07-20
CA3007311A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
WO2017100305A8 (en) Composition of antibody construct-agonist conjugates and methods of use thereof
AR125320A2 (en) CRYSTALLINE COMPOUND, METHOD OF PREPARATION AND COMPOSITION INCLUDING IT
WO2020039321A8 (en) Anti-gdf15 antibodies, compositions and methods of use
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
EP3642182A4 (en) Compounds, compositions and methods for synthesis
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2019014514A (en) Compounds for treating huntington's disease.
EP4279071A3 (en) Novel cannabinoid formulations
WO2017173415A3 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
WO2015192127A3 (en) Formulated receptor polypeptides and related methods
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
WO2017214462A3 (en) Anti-cd98 antibodies and antibody drug conjugates
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
WO2015164392A3 (en) Novel antii-rnf43 antibodies and methods of use
WO2017214170A3 (en) Baff-r antibodies and uses thereof
EP3279207A4 (en) Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2015054600A3 (en) Glycan-interacting compounds and methods of use
MX2019003818A (en) 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivative and method for synthesizing optical isomer thereof.
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
WO2017042828A3 (en) Process for the preparation of selexipag
WO2016102672A3 (en) Inhibitors of akt kinase
WO2017064627A3 (en) Process for preparation of eribulin and intermediates thereof
WO2016020702A8 (en) Anti-tenascin c antibodies and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 212016000029

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16873755

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3007311

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2016873755

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016873755

Country of ref document: EP

Effective date: 20180709

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16873755

Country of ref document: EP

Kind code of ref document: A2